Since the last renewal, the previous Tissue Procurement Facility and Research Histology Shared Resource have merged and expanded their functions to form the Biorepository and Tissue Research Facility (BTRF), under new leadership. The BTRF makes human biospecimens available for basic, translational, and clinical research. It is the major conduit through which human tissue specimens are transferred from the Pathology, Surgery and other clinical departments to research labs at the University of Virginia (UVA), and is the major processor of human biospecimens (tissue, blood, urine) in support of clinical trials at UVA. In addition, this is the only shared research facility that supports standard histology services and complex histology-based analytic techniques for animal models and human tissues, including tissue microarray construction, laser microdissection, immunohistochemistry, digital slide scanning and reverse-phase protein microarrays. Expert histopathology support from Board-certified Anatomic Pathologists is provided for these activities through this Shared Resource. The biorepository and analytic services are often vertically integrated with each other to allow for """"""""one-stop shopping"""""""" for investigators carrying out translational or clinical cancer research. BTRF services make possible new insights into cancer disease mechanisms by the analysis of tissues and biofluids, assist in the discovery and validation of new clinical cancer biomarkers, and support clinical trials of novel diagnostic tests and therapies for cancer.
Analysis of human tissues is the conduit through which new knowledge about molecules and cells enters the realm of clinical practice. The BTRF provides both tissues and analytic tools to advance cancer diagnosis, prognosis, and treatment.
|Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5|
|Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :|
|Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275|
|Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679|
|Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369|
|Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255|
|Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :|
|Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437|
|Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655|
|Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442|
Showing the most recent 10 out of 539 publications